Amphastar Pharmaceuticals (AMPH) Change in Receivables (2013 - 2026)

Amphastar Pharmaceuticals' Change in Receivables history runs 14 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 43.69% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $2.8 million (down 56.62% YoY), while the FY2025 annual figure was $6.4 million, down 70.62% from the prior year.
• Change in Receivables was $4.5 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$3.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $23.2 million in Q1 2024 to a low of -$12.3 million in Q2 2025.
• Historically, Change in Receivables has averaged $4.0 million across 5 years, with a median of $4.5 million in 2026.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables soared 1430.46% in 2022, then tumbled 428.82% in 2024.
• A 5-year view of Change in Receivables shows it stood at $11.6 million in 2022, then slumped by 135.39% to -$4.1 million in 2023, then gained by 28.93% to -$2.9 million in 2024, then fell by 11.22% to -$3.2 million in 2025, then jumped by 240.69% to $4.5 million in 2026.
• The last three Change in Receivables figures came in at $4.5 million (Q1 2026), -$3.2 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.